Shut Down
Trigemina Stock
Trigemina develops non-opiate drug formulations and delivery systems for pain therapy.
Sign up today and learn more about Trigemina Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Trigemina Stock
Trigemina, Inc. develops non-opiate drug formulations and delivery systems for the pain therapy. The company’s products include TI-001, an intranasal oxytocin that targets chronic and sub-acute head pain; and TI-002, a non-opioid treatment that addresses a range of pain, including neuropathic pain throughout the body. Its drugs are delivered via the nasal-cerebral pathway. The company was founded in 2006 and is based in Mountain View, California.
Funding History
| December 2006 | $2.0M |
|---|---|
| December 2009 | $305K |
| October 2010 | $400K |
| April 2014 | $8.0M |
| June 2015 | $10.0M |
| July 2017 | $2.4M |
Management
Chief Medical Officer
Shashidhar Kori
Co-Founder
Martin Angst
Co-Founder
William Frey II
Chief Medical Advisor
Stephen Silberstein
Founder, Chief Scientist
David C Yeomans
Chairman
Charles Yeomans
Chief Financial Officer & Chief Operating Officer
Michael Leonard
Press
prnewswire - Jan, 15 2016
Trigemina to Present at Biotech Showcase 2016prnewswire - Dec, 19 2015
Trigemina Publishes Data Demonstrating that the Activation of Oxytocin Receptors May Provide Clinical Benefit to Migraine Patientsventurebeat - May, 20 2015
Trigemina takes $305K to treat recurring pain | VentureBeat | Deals | by Camille RickettsEquityZen Recognized As:
